FDA Delays Abortion Pill Review as Trump Accounts Enrollment Reaches Milestone

The U.S. Food and Drug Administration has announced that its safety review of the abortion pill mifepristone will not be completed until March 2027. This timeline has drawn criticism from pro-life leaders, who have expressed frustration regarding the agency's pace in addressing the matter.

In other administration developments, President Donald Trump confirmed that all eligible minor children in the United States have been enrolled in the newly established Trump Accounts. According to the White House, more than $4.5 billion has been deposited into these investment accounts since the program's launch on July 4. These updates occurred as the administration continues to hold rallies in anticipation of the upcoming midterm elections on November 3.